TITLE:
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

CONDITION:
HIV Infections

INTERVENTION:
Saquinavir

SUMMARY:

      To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the
      treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.
    

DETAILED DESCRIPTION:

      All enrolled patients will receive the following 3 drug combination: Saquinavir, Zidovudine
      and Lamivudine. Efficacy and duration of anti-viral response will be evaluated by monitoring
      of HIV-1 RNA levels. Patients below the detectable limit of 200 copies/ml will be analyzed
      using the Ultra-direct method with a detection limit of 20 copies/ml. CD4 and CD8 cell
      counts will also be analyzed.
    

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Plasma HIV-1 RNA titers > 10,000 copies/ml.

          -  CD4 cell count > 100 cells/mm3.

        Exclusion Criteria

        Co-existing Condition:

        Patients with any of the following conditions will be excluded:

          -  Any prior anti-retroviral drug therapy.

        Prior Medication:

        Excluded:

        Previous anti-retroviral drug therapy.
      
